Holen Sie sich die Stockscreener-App
2.74
4.98%
0.13
Handel nachbörslich:
2.89
0.15
+5.47%
Inflarx Nv Aktie (IFRX) Neueste Nachrichten
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
Long term debt to total assets ratio of InflaRx N.V. – HAM:IF0 - TradingView
Discontinued operations of InflaRx N.V. – HAM:IF0 - TradingView
EBIT per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. Cash Flow – HAM:IF0 - TradingView
InflaRx N.V. Balance Sheet – HAM:IF0 - TradingView
InflaRx N.V. Statistics – HAM:IF0 - TradingView
Non-controlling/minority interest of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slo - AD HOC NEWS
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Nigeria
IFRX Technical Analysis | Trend, Signals & Chart Patterns | INFLARX NV (NASDAQ:IFRX) - ChartMill
InflaRx NV stock (NL0012661870): May data from a recent YTD ranking - AD HOC NEWS
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
Raymond James upgrades InflaRx NV (IFRX) - MSN
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential - Investing.com UK
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential By Investing.com - Investing.com South Africa
InflaRx NV Stock (IFRX): Favorable Izicopan Data Released - AD HOC NEWS
TradingKey - TradingKey
TCG Crossover III and Chen Yu disclose 9.8% stake in InflaRx (IFRX) - Stock Titan
InflaRx NV stock (NL0012661870): HC Wainwright raises price target to $8 - AD HOC NEWS
Number of shareholders of InflaRx N.V. – NASDAQ:IFRX - TradingView
Number of shareholders of InflaRx N.V. – TRADEGATE:IF0 - TradingView
InflaRx N.V. Completes $150 Million Underwritten Offering of Ordinary Shares to Advance Pipeline Activities - Moomoo
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026 - The Globe and Mail
IFRX - Finviz
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal DiseasesSlideshow (NASDAQ:IFRX) 2026-05-08 - Seeking Alpha
Transcript : InflaRx N.V.Special Call - marketscreener.com
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - Barchart.com
InflaRx Unveils Izicopan Strategic Shift And $150m Offering - Citeline News & Insights
InflaRx completes $150 million stock offering at $2 per share By Investing.com - Investing.com Australia
InflaRx completes $150 million stock offering at $2 per share - Investing.com
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - The Manila Times
75 million new InflaRx shares raise cash to fund drug pipeline - Stock Titan
Press Release: InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - Moomoo
InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale - Stock Titan
EDGAR Filing Documents for 0001140361-26-019440 - SEC.gov
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq - Insider Monkey
InflaRx (NASDAQ: IFRX) raises $150M via 75M-share offering to fund izicopan - Stock Titan
Form 424B5 InflaRx N.V. - StreetInsider
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx attracts strong investor interest with US share offering turning to kidney - European Biotechnology Magazine
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):